The optimization of recombinant antibody production within Chinese hamster ovary (CHO) cells remains a paramount challenge for the biopharmaceutical industry. Various strategies can be employed enhance antibody titer, comprising process parameter optimization, genetic engineering, and adoption of perfusion systems. Fine-tuning growth parameters p